Shares in Redx Pharma were under pressure today following the announcement that it would not be advancing its cancer drug candidate RXC004 into phase 3 testing in biliary tract cancer, after it failed ...

It ain’t over ‘til it’s over and for Redx Pharma, it’s over. Redx and Jounce Therapeutics announced Monday morning that the two companies agreed to terminate their proposed business combination ...

March 27 (Reuters) - Jounce Therapeutics Inc on Monday agreed to be acquired by privately held Concentra Biosciences for $96.46 million, while spurning a merger deal with British biotech firm Redx ...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise well ...

A $425 million proposed marriage between Redx Pharma of the UK and Jounce Therapeutics is on the rocks, just over a month after it was first announced. Jounce has instead thrown its lot in with ...

There’s significant change on the way at Jounce Therapeutics. The embattled clinical-stage company announced Wednesday afternoon that it is laying off more than half of its workforce as part of a ...

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announced that ...

Simply sign up to the UK companies myFT Digest -- delivered directly to your inbox. Trading of shares in Redx, a UK pharmaceuticals company, resumed after five months on Monday when the slimmed-down ...